Figure 3From: A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time Comparing immune responses with PSA kinetics. (A) Change in PSA from baseline (%) based on immune responses. (B) Ratio of PSADT based on immune responses.Back to article page